卵巢癌化疗期间的运动与久坐时间是否与治疗相关副作用、化疗完成率及生存相关
基于OPAL前瞻性队列503例新诊断上皮性卵巢癌患者,评估化疗期间运动与久坐时间是否与副作用、化疗完成(相对剂量强度≥85%)及生存相关。较高强度运动者FACIT-疲劳及FACT-TOI评分更优,临床医生报告的中重度神经毒性更少(OR 0.50,95%CI 0.29-0.88),化疗完成可能更好(OR 1.70,95%CI 0.90-3.20),晚期患者生存可能改善(HR 0.68,95%CI 0.47-1.01)。久坐时间与化疗完成无关。
要点
- 较高强度运动者FACIT-疲劳评分32.2 vs 26.7,FACT-TOI 69.4 vs 61.7,均优于极低运动者。
- 较高强度运动者临床医生报告的中重度神经毒性更少(OR 0.50,95%CI 0.29-0.88)。
- 晚期患者较高强度运动可能改善生存(HR 0.68,95%CI 0.47-1.01),久坐时间与化疗完成无关。
核心结论
- 卵巢癌患者化疗期间进行中高强度运动与更少副作用相关,并可能提高计划化疗完成率和总生存。
研究设计与样本
- OPAL研究为全国性前瞻性队列,纳入新诊断上皮性卵巢癌成人患者,每3个月问卷评估过去一周运动与久坐时间及治疗相关副作用。
- 共503例符合条件参与者纳入一项或多项分析,治疗、毒性、进展和死亡信息从病历摘录。
- 采用线性、逻辑和Cox回归分别评估运动与久坐时间和化疗副作用、化疗完成(相对剂量强度≥85%)及生存的关联。
主要发现
- 较高强度运动者(每周中高强度运动≥30分钟,占24%)FACIT-疲劳评分32.2 vs 极低运动者(每周中高强度运动<30分钟且步行<120分钟,占52%)26.7。
- 较高强度运动者FACT-TOI评分69.4 vs 极低运动者61.7。
- 较高强度运动者临床医生报告中重度神经毒性更少(OR 0.50,95%CI 0.29-0.88)。
- 较高强度运动与化疗完成可能相关(OR 1.70,95%CI 0.90-3.20),尤其对紫杉醇。
- 晚期接受减瘤术并一线卡铂联合紫杉醇患者中,化疗期间较高强度运动可能改善生存(HR 0.68,95%CI 0.47-1.01)。
关键数值与推荐
- 较高强度运动定义为每周中高强度运动≥30分钟;极低运动定义为每周中高强度运动<30分钟且步行<120分钟。
- 化疗完成定义为相对剂量强度≥85%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate if exercise and sitting time during chemotherapy were associated with chemotherapy side-effects, completion of planned chemotherapy and survival. METHODS: We used data from the Ovarian cancer Prognosis And Lifestyle (OPAL) Study, a national prospective cohort of adults with newly-diagnosed epithelial ovarian cancer. At 3-monthly questionnaires we asked about exercise and sitting time in the past week, and treatment-related side-effects. Details about treatment, toxicities, progression and death were abstracted from medical records. We used linear, logistic and Cox regression, respectively, to assess associations between both exercise and sitting time, and chemotherapy side-effects and completion (≥85% relative dose intensity) and survival. RESULTS: 503 eligible participants were included in one or more analyses. Patients participating in higher-intensity exercise (≥30 min of moderate-vigorous exercise/week; 24%) reported significantly better Functional Assessment of Chronic Illness/Cancer Therapy (FACIT)-Fatigue (32.2 vs. 26.7) and FACT-Trial Outcome Index (69.4 vs. 61.7) scores, and were less likely to have clinician-reported moderate-severe neurotoxicity (odds ratio [OR]:0.50; 95% confidence interval [95%CI]:0.29-0.88), than minimal exercisers (<30 min moderate-vigorous exercise/week & <120 min walking/week; 52%). Participating in higher-intensity exercise was also possibly associated with greater chemotherapy completion (OR:1.70; 95%CI:0.90-3.20), particularly for paclitaxel. Sitting time was not associated with chemotherapy completion. For patients with advanced disease who underwent cytoreduction and received first-line carboplatin and paclitaxel, there was a suggestion higher-intensity exercise during chemotherapy may improve survival (HR:0.68; 95%CI:0.47-1.01). CONCLUSIONS: Patients with ovarian cancer who carry out moderate-vigorous exercise during chemotherapy have fewer side-effects and potentially better completion of planned chemotherapy and overall survival.
引用
- Ross TL, Na R, Au-Yeung G, et al. Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival? Gynecol Oncol. 2024. PMID: 39146755. doi:10.1016/j.ygyno.2024.07.684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。